Portfolio company
cystetic Medicines
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This clinical-stage biotechnology company develops inhalable small molecule therapeutics to restore lung function in patients with cystic fibrosis.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Kither Biotech
This company develops inhaled therapies for patients with respiratory diseases such as chronic obstructive pulmonary disease and cystic fibrosis.
Endeavor BioMedicines
This clinical-stage biotechnology company develops small-molecule inhibitors and therapies for patients with oncology and fibrotic lung diseases.
ReCode Therapeutics
This company develops mRNA and gene correction therapies delivered via lipid nanoparticles for patients with cystic fibrosis and primary ciliary dyskinesia.
AirNexis
This clinical-stage biotechnology company develops inhaled therapies for patients with chronic obstructive pulmonary disease and other respiratory conditions.
AirNexis Therapeutics
This company develops inhaled small molecule medicines to treat chronic obstructive pulmonary disease for patients with respiratory conditions.
Clarametyx Biosciences
This company develops immune-enabling therapies targeting bacterial biofilms for patients with chronic and progressive respiratory diseases.
Breath Therapeutics
This biopharmaceutical company develops inhaled drug-aerosol therapies for patients with bronchiolitis obliterans syndrome and other severe respiratory diseases.
Calluna Pharma
This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.